

NIH funding opportunities

01 Nov 2023 (#34)



Confirm your intent to apply *ASAP*, but not later than *60 days* before the submission date.



See all Important Notices, Parent Announcements and Notice of Special Interest below

Plan your application. Before starting your application attend

- 1) *Generic Grant Writing Workshop and then the*
- 2) *NIH Grant Writing Workshop*

To prepare an application can take *4-18 months*.

From submission to receiving a Notice of Award can take *10 months*

Important Notices

[NOT-OD-23-185](#) Prior Approval Requests for Revisions to an Approved Data Management and Sharing (DMS) Plan Must be Submitted Using the Prior Approval Module. The purpose of this Notice is to remind the extramural research community that any changes to an approved [Data Management and Sharing Plan \(DMS Plan\)](#) (for funded awards subject to the [Final NIH Policy for Data Management and Sharing \(DMS\) Policy](#)) requires the recipient to submit a timely formal prior approval request to the funding NIH Institute, Center, or Office (ICO). This notice also informs the community that recipients must submit these requests through the Prior Approval Module in eRA Commons.

Parent Announcements

[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities. Current Key Dates
Expiration Date: May 8, 2023. Modified Expiration Date: May 8, 2024

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

[NOT-AI-23-070](#) Ending the HIV Epidemic (EHE). The objective of this Notice of Special Interest (NOSI) is to solicit applications proposing research that is grounded in implementation science and can address the goals of the [Ending the HIV Epidemic in the U.S. \(EHE\)](#) initiative. The overall objective of EHE is to address the ongoing public health crisis with goals of first reducing the number of incident infections in the U.S. by 75% by 2025, and at least 90% by 2030, compared to the baseline infection rate in 2017. Projects will leverage research-community collaborations and scientific advances in HIV prevention, diagnosis, treatment, and outbreak response to advance the EHE goals, using innovations to tailor strategies for the multi-level barriers and strengths in communities disproportionately impacted by HIV. This notice applies to due dates on or after January 7, 2024. Submit applications for this initiative using one of the NOFO's listed or any reissues of these announcements through the expiration date of this notice.

Notice of Funding Opportunity (NOFO)

1. [PAR-23-301](#) Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)

The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.

Due dates: February 16, 2024 through to November 16, 2026. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

2. [PAR-23-302](#) Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)

The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets.

Due Date: February 05, 2024 through to November 05, 2026. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/Research Contact at least 6 weeks before submitting the application.

3. [RFA-AI-23-054](#) Fc-Dependent Mechanisms of Antibody-Mediated Killing (R01 Clinical Trial Not Allowed)

The purpose of this notice of funding opportunity (NOFO) is to support basic research that will elucidate mechanisms of Fc-mediated antibody functions, including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). Supported studies are expected to generate foundational data and tools that can be applied to the prediction of Fc-mediated killing activity by antibodies. Such data should accelerate development of therapeutic monoclonal antibodies and design of vaccines or vaccine-adjuvant combinations that induce antibody responses capable of killing infected host cells, particularly in cases where induction of neutralizing antibodies fails or is insufficient for clearance of infection.

Due Date: January 26, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: NIAID intends to commit \$ 2.0M in FY 2025 to fund 3-4 awards. Application budgets are not expected to exceed \$300,000 direct costs per year but need to reflect the actual needs of the proposed project. The maximum project period is five years.

4. [RFA-DA-24-005](#) Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Clinical Trials Optional)

The purpose of this notice of funding opportunity (NOFO) is to solicit applications for research aimed at elucidating neurobiological mechanisms underlying the influence of psychosocial stress on substance use disorders (SUDs) and co-occurring psychiatric disorders in people living with HIV (PLWH). This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.

Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available [PEDP guidance material](#).

Due Date: February 15, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: NIDA intends to commit \$3M in FY 2024 to fund up to six awards across this NOFO and the companion NOFO [RFA-DA-24-006](#). Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) are strongly encouraged to contact the Scientific/Research Contact listed in Section VII of this announcement at least 6 weeks prior to submission. The scope of the proposed project should determine the project period. The maximum project period is five years.

5. [RFA-DA-24-006](#) Mechanistic Studies of the Effects of Psychosocial Stress on Complex Morbidity Involving SUD, Psychiatric Disorders, and HIV (R01 Basic Experimental Studies with Humans (BESH) Required)

The purpose of this notice of funding opportunity (NOFO) is to solicit applications for basic science experiments involving humans (BESH) aimed at elucidating neurobiological mechanisms underlying the influence of psychosocial stress on neurobehavioral function and risk for substance use disorders (SUD) and co-occurring psychiatric disorders in people living with HIV (PLWH). As referred to in [NOT-OD-18-212](#), BESH are “prospective basic science studies involving human participants” that fall within the NIH definition of a clinical trial and also meet the definition of basic research. Such studies prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental processes or principles. Applicants proposing projects involving animal models or observational studies in humans should use the companion NOFO, [RFA-DA-24-005](#). This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation.

Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available [PEDP guidance material](#).

Due Date: February 15, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: NIDA intends to commit \$3.0M in FY 2024 to fund up to six awards across this NOFO and the companion NOFO, [RFA-DA-24-005](#). The proposed budget must reflect the actual needs of the proposed project. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) are strongly advised to contact the Scientific/ Research Contact listed in Section VII of this announcement at least 6 weeks before submitting the application. The scope of the proposed project should determine the project period. The maximum project period is five years.

6. [RFA-DA-25-017](#) Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R21 Clinical Trial Not Allowed)

The purpose of this notice of funding opportunity (NOFO) is to support data mining of single cell data sets to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/antiretroviral therapy (ART) or Substance Use Disorder (SUD)-relevant molecular responses, and/or to support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening) to confirm or deny a biological role for one or more of the data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART and SUD molecular responses. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be

assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available [PEDP guidance material](#).

Due Date: August 13, 2024. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The total project period may not exceed 2 years.

7. [RFA-DA-24-031](#) Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Clinical Trial Optional)

The purpose of this notice of funding opportunity (NOFO) is to encourage clinical research that will identify and validate 1) Novel targets for non-invasive brain stimulation (NIBS) and 2) Substance use disorder (SUD)-relevant neurobiological, cognitive, and behavioral responses to NIBS that may precede clinical outcomes like reduced craving or substance use. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available [PEDP guidance material](#).

Due Date: January 16, 2024 through to August 14, 2026. Due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Letter of Intent:** 30 days prior to the application due date

Budget: NIDA intends to commit \$1.5M in FYs 2024, 2025, and 2026 to fund up to six awards in response to this NOFO and the **companion NOFOs** [RFA-DA-24-032](#), [RFA-DA-24-033](#), and [RFA-DA-24-034](#). Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the requested project period. The maximum project period is 5 years.

Faculty of Medicine and Health Sciences Research & Internationalisation Development & Support (RIDS) & Grants Management Office (GMO) 009 K th Floor, Teaching Block, Tygerberg Campus.	Stellenbosch Campus Division for Research Development (DRD) 2041 Krotoa Building, Ryneveld Street
Enquiries: fmhsgmo@sun.ac.za	Enquiries: research@sun.ac.za
Add "Interest in NIH opportunity" in the subject line. Add the notice number in the text of the email.	